Obesity drug Contrave met its main goals in three late-stage clinical trials

And also surpassed a FDA requirement for effectiveness.
Patients who took Contrave had significantly greater weight loss than those who took a placebo, and the drug reduced other risk factors like waist circumference, the company said. For diabetes patients, the drug also diminished blood sugar levels.
The San Diego-based company said it plans to seek FDA approval for Contrave in early 2010. Orexigen said the drug also tempered food cravings and allowed patients to better control their eating.

Read more on: The Associated Press